The purpose of this study is to determine the efficacy, safety and tolerability of two previously approved medicines, dolutegravir (DTG) plus rilpivirine (RPV) dosed together, compared with subjects taking their current antiretroviral regimen (CAR) for the treatment of HIV-1 infected adults in whom the HIV-1 virus is currently suppressed. This study will enroll people living with HIV and who currently have a suppressed HIV viral load. The two drug regimen of DTG and RPV is considered experimental and is not yet approved to treat patients with HIV-1. About 476 men and women in up to 15 countries will take part in this study and 5 individuals will potentially be enrolled from St. Michael’s Hospital.

This trial is sponsored by Glaxo Smith Kline.